Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Olaparib monotherapy for BRCA-mutated platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Olaparib in combination with bevacizumab for ovarian, fallopian tube or primary peritoneal cancer – maintenance therapy	Bevacizumab (Avastin; R 435; RG 405; RG 435) , Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Fallopian tube cancer , Ovarian cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Olaparib for BRCAm or ATM mutated metastatic castration-resistant prostate cancer	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Ofatumumab for relapsing multiple sclerosis	Ofatumumab (Arzerra)	Multiple sclerosis (MS)	Neurology	2019	View \| Download
Obeticholic acid for non-alcoholic steatohepatitis and fibrosis	Obeticholic Acid (Ocaliva; INT-747)	Non-alcoholic steatohepatitis (NASH)	Hepatology	2019	View \| Download
NOVOCART 3D for articular cartilage defects of the knee	Autologous Chondrocyte Implant (NOVOCART 3D)	Articular cartilage defects	Musculoskeletal System	2019	View \| Download
Nivolumab in combination with rucaparib for metastatic castration-resistant prostate cancer with prior chemotherapy	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab in combination with rucaparib for chemotherapy naive metastatic castration-resistant prostate cancer	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Enzalutamide (Xtandi; MDV3100) , Nivolumab (Opdivo; BMS-936558; ONO-4538) , Rucaparib (Rubraca; PF-1367338)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab for the adjuvant treatment of melanoma	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Melanoma	Skin Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab for oesophageal squamous cell carcinoma – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Oesophageal cancer	Head and Neck Cancer	2019	View \| Download